mutation class

Small Mutation

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

315 sites for NCT04497844

ATM Loss, +61 more biomarkers

Prostate Adenocarcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

106 sites for NCT03742895

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

267 sites for NCT03994796

AKT1 Amplification, +52 more biomarkers

Malignant Solid Tumor

abemaciclib, +2 more drugs

targeted therapy

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

48 sites for NCT04632992

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

440 sites for NCT02523014

AKT1 Mutation, +13 more biomarkers

Intracranial Meningioma

abemaciclib, +3 more drugs

targeted therapy